{"componentChunkName":"component---src-templates-study-details-page-js","path":"/en/study/ESS 30005","result":{"data":{"studyNotFoundJson":{"title":"Study not found","content":{"childMarkdownRemark":{"html":"<p>If you entered a web address please check it was correct.</p>\n<p>You can also try <a href=\"/en/studies\">Search Page</a> to find the study you are looking for.</p>"}}},"trialDetailsJson":{"title":"Details Page","returnSearch":"Back to search results","description":"Study Description","identifier":"ViiV Study ID","clinicalID":"Clinicaltrials.gov Identifier","EudraCtID":"EudraCT Number","resultsAvailable":"Has Results Available Below","docAvailable":"Has Results Document Available","studyOverview":"Study Overview","overviewSection":{"conditionsDisplay":"Medical Conditions","product":"Product","collaborators":"Collaborators","dates":"Date","studyType":"Type","phase":"Phase","gender":"Gender","age":"Age","acceptVolunteers":"Accepts Healthy Volunteers"},"studyDocuments":"Study Documents","noDocuments":"No documents available","studyDocumentsAdditionalText":"If you wish to request for Full Study Report, please contact - ","studyDocumentsAdditionalEmail":"GSKClinicalSupportHD@gsk.com","isReleased":{"firstPart":"This study has Protocol and Result summary on ClinicalTrial.gov. Click","secondPart":"to learn more.","linkText":"here"},"mapLocations":"Locations","centralContact":"Central Contact","centralPhone":"Central Contact Phone","centralEmail":"Central Contact Email","mapSection":{"site":"GSK Investigational Site","condition":"Condition","id":"Study ID","city":"City","state":"State","zip":"Zip","country":"Country"},"studyDesign":"Study Design","designSection":{"purpose":"Primary Purpose","allocation":"Allocation","study_design":"Study Design","study_classification":"Study Classification","masking":"Masking","masked_subject":"Masked Subject","masked_caregiver":"Masked Caregiver","masked_investigator":"Masked Investigator","masked_assessor":"Masked Assessor","primary_outcomes":"Primary Outcomes","secondary_outcomes":"Secondary Outcomes","arms":"Arms","interventions":"Interventions","keyword":"Keyword","inclusionTitle":"Inclusion Criteria","exclusionTitle":"Exclusion Criteria","criteriaText":"Inclusion/Exclusion Criteria","criteria_button":"Click to view inclusion/exclusion criteria","enrollment":"Enrollment","clinicalPublications":"Clinical Publications"},"popoversText":{"studyId":{"childMarkdownRemark":{"html":"<p>A unique number for a study given by ViiV.</p>"}},"ctGov":{"childMarkdownRemark":{"html":"<p>This number identifies the study on the US clinicaltrials.gov register. Click this link to go to the entry for this study on Clinicaltrials.gov where you will be able to see protocol and results summaries where available.</p>"}},"eudraCT":{"childMarkdownRemark":{"html":"<p>This number identifies the study on the EU clinicaltrials.eu register. Click this link to go to the entry for this study on clinicaltrials.eu where you will be able to see protocol and results summaries where available.</p>"}}}},"site":{"siteMetadata":{"siteUrl":"https://www.viiv-studyregister.com"}},"studyDetails":{"nct_number":"NCT00038506","ctis_id":"","HasResults":"false","IpdAccessCriteria":"","IpdDescription":"","IpdInfoTypeAnalyticCode":"","IpdInfoTypeIcf":"","IpdInfoTypeCsr":"","IpdInfoTypeProtocol":"","IpdInfoTypeSap":"","IpdTimeFrame":"","IpdUrl":"","IsFlexibleTrial":false,"IsReleasedToCtGov":"true","MaskingInfo":{"masked_assessor":"","masked_caregiver":"","masked_investigator":"","masked_subject":"","masking_description":"","no_masking":""},"PatientLevelData":"false","SharingIpd":"","acronym":"","allocation":"Non-randomized","arm_groups":[],"assignment":"Single Group Assignment","brief_summary":"This study is a 48-week study to evaluate the efficacy and safety of an investigational regimen combining FDA approved HIV drugs in antiretroviral-experienced subjects failing on their first highly active antiretroviral therapy regimen.","brief_summary_OneLinkTx":"","brief_title_OneLinkTx":"","brief_title":"Study Of Investigational Regimen Combining FDA Approved HIV Drugs In HIV Subjects Experiencing Early Virologic Failure","conditions":[{"DisplayValue":"Human Immunodeficiency Virus (HIV)","DisplayValue_OneLinkTx":"","InternalValue":"CON_HIV","LookupValue":"HIV Infection","LookupValue_OneLinkTx":""}],"created_date":"09/15/2018 18:05:01","criteria":"Inclusion Criteria: - Currently on an initial HAART (highly active antiretroviral therapy) regimen of 3TC/ZDV or 3TC/d4T and a PI (protease inhibitor) -boosted or unboosted- or NNRTI (non-nucleoside reverse transcriptase inhibitor). - Plasma HIV - 1 RNA was <400 copies/ml on at least 2 documented occasions prior to viral rebound. - Have a plasma HIV - 1 RNA value >400 copies/ml and <10,000 copies/ml on 2 documented successive occasions (including screen) separated by at least 2 weeks. - A CD4+ lymphocyte count less than or equal to 100. Exclusion Criteria: - Have not taken Abacavir (ZIAGEN or TRIZIVIR) or tenofovir (VIREAD) previously. - Have not had an AIDS defining illness within 30 days of screen. - Pregnant or breast-feeding. - Specified viral genotypes upon screening. - And other inclusion or exclusion criteria to be evaluated by the physician.","detailed_description":"","display_gender":"Both","display_gender_internal":"GENDER_ALL","display_phase":"Phase 4","display_phase_internal":"PHASE_4","display_status":"Completed","display_status_internal":"RECSTATUS_I_COMPLETED","endpoint":"","enrollment":"100","exclusion":"","gender":"Both","gender_based":"","gender_description":"","healthy_volunteers":"no","id":"b244c037-3f98-5b72-a454-c6040bf9e481","internal":{"content":null,"contentDigest":"bbafcb0029e1d2c93524b76678cc180e","description":null,"fieldOwners":null,"mediaType":null,"ignoreType":null,"owner":"default-site-plugin","type":"studyDetails"},"inclusion":"Inclusion Criteria: - Currently on an initial HAART (highly active antiretroviral therapy) regimen of 3TC/ZDV or 3TC/d4T and a PI (protease inhibitor) -boosted or unboosted- or NNRTI (non-nucleoside reverse transcriptase inhibitor). - Plasma HIV - 1 RNA was <400 copies/ml on at least 2 documented occasions prior to viral rebound. - Have a plasma HIV - 1 RNA value >400 copies/ml and <10,000 copies/ml on 2 documented successive occasions (including screen) separated by at least 2 weeks. - A CD4+ lymphocyte count less than or equal to 100. Exclusion Criteria: - Have not taken Abacavir (ZIAGEN or TRIZIVIR) or tenofovir (VIREAD) previously. - Have not had an AIDS defining illness within 30 days of screen. - Pregnant or breast-feeding. - Specified viral genotypes upon screening. - And other inclusion or exclusion criteria to be evaluated by the physician.","interventions":[{"arm_group_label":"","intervention_description":"","intervention_name":"abacavir/lamivudine/zidovudine","intervention_type":"Drug"},{"arm_group_label":"","intervention_description":"","intervention_name":"tenofovir","intervention_type":"Drug"}],"interventional_subtype":"Treatment","is_fda_regulated":null,"is_high_value":false,"is_ind_study":true,"keywords":["HIV-1 TRIZIVIR Tenofovir"],"last_follow_up_date":"08/01/2004 00:00:00","links":[],"locations":[{"City":"Fort Lauderdale","Latitude":"25.750008","CountryDisplay":"United States","Longitude":"-80.241826","Name":"GSK Investigational Site","StateDisplay":"Florida","PostalCode":"33145","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Arlington","Latitude":"32.6905101","CountryDisplay":"United States","Longitude":"-97.1305536","Name":"GSK Investigational Site","StateDisplay":"Texas","PostalCode":"76015","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Valhalla","Latitude":"41.085128","CountryDisplay":"United States","Longitude":"-73.7772032","Name":"GSK Investigational Site","StateDisplay":"New York","PostalCode":"10595","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"North Miami","Latitude":"25.8900949","CountryDisplay":"United States","Longitude":"-80.1867138","Name":"GSK Investigational Site","StateDisplay":"Florida","PostalCode":"33161","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Dallas","Latitude":"32.7962048","CountryDisplay":"United States","Longitude":"-96.7694752","Name":"GSK Investigational Site","StateDisplay":"Texas","PostalCode":"75246","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Miami","Latitude":"25.7870967","CountryDisplay":"United States","Longitude":"-80.2042436","Name":"GSK Investigational Site","StateDisplay":"Florida","PostalCode":"33136","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"San Rafael","Latitude":"38.0270044","CountryDisplay":"United States","Longitude":"-122.5485873","Name":"GSK Investigational Site","StateDisplay":"California","PostalCode":"94903","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Dallas","Latitude":"32.7030883","CountryDisplay":"United States","Longitude":"-96.8029489","Name":"GSK Investigational Site","StateDisplay":"Texas","PostalCode":"75216","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Berkeley","Latitude":"42.5007019","CountryDisplay":"United States","Longitude":"-83.1916937","Name":"GSK Investigational Site","StateDisplay":"Michigan","PostalCode":"48072","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Lake Worth","Latitude":"26.6064003","CountryDisplay":"United States","Longitude":"-80.1316927","Name":"GSK Investigational Site","StateDisplay":"Florida","PostalCode":"33463","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Orlando","Latitude":"28.5747416","CountryDisplay":"United States","Longitude":"-81.3949264","Name":"GSK Investigational Site","StateDisplay":"Florida","PostalCode":"32804","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Decatur","Latitude":"33.8092255","CountryDisplay":"United States","Longitude":"-84.2805478","Name":"GSK Investigational Site","StateDisplay":"Georgia","PostalCode":"30033","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Green Bay","Latitude":"44.4812116","CountryDisplay":"United States","Longitude":"-88.0167406","Name":"GSK Investigational Site","StateDisplay":"Wisconsin","PostalCode":"54301","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Houston","Latitude":"29.7209034","CountryDisplay":"United States","Longitude":"-95.3677844","Name":"GSK Investigational Site","StateDisplay":"Texas","PostalCode":"77004","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Bronx","Latitude":"40.8476284","CountryDisplay":"United States","Longitude":"-73.8360251","Name":"GSK Investigational Site","StateDisplay":"New York","PostalCode":"10461","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Atlanta","Latitude":"33.7971137","CountryDisplay":"United States","Longitude":"-84.3804888","Name":"GSK Investigational Site","StateDisplay":"Georgia","PostalCode":"30309","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"New York","Latitude":"40.7366138","CountryDisplay":"United States","Longitude":"-74.0094471","Name":"GSK Investigational Site","StateDisplay":"New York","PostalCode":"10014","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Dallas","Latitude":"32.7457134","CountryDisplay":"United States","Longitude":"-96.8458204","Name":"GSK Investigational Site","StateDisplay":"Texas","PostalCode":"75208","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Seattle","Latitude":"47.6015566","CountryDisplay":"United States","Longitude":"-122.3323351","Name":"GSK Investigational Site","StateDisplay":"Washington","PostalCode":"98104","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Lafayette","Latitude":"40.4350547","CountryDisplay":"United States","Longitude":"-86.8772298","Name":"GSK Investigational Site","StateDisplay":"Indiana","PostalCode":"47904","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Miami Beach","Latitude":"25.783312","CountryDisplay":"United States","Longitude":"-80.1484407","Name":"GSK Investigational Site","StateDisplay":"Florida","PostalCode":"33139","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Los Angeles","Latitude":"34.1220545","CountryDisplay":"United States","Longitude":"-118.2935891","Name":"GSK Investigational Site","StateDisplay":"California","PostalCode":"90027","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Chicago","Latitude":"41.9403795","CountryDisplay":"United States","Longitude":"-87.6531805","Name":"GSK Investigational Site","StateDisplay":"Illinois","PostalCode":"60657","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Jacksonville","Latitude":"30.346791","CountryDisplay":"United States","Longitude":"-81.6418656","Name":"GSK Investigational Site","StateDisplay":"Florida","PostalCode":"32206","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Maywood","Latitude":"41.8791979","CountryDisplay":"United States","Longitude":"-87.8431155","Name":"GSK Investigational Site","StateDisplay":"Illinois","PostalCode":"60153","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Tallahassee","Latitude":"30.5099431","CountryDisplay":"United States","Longitude":"-84.3647199","Name":"GSK Investigational Site","StateDisplay":"Florida","PostalCode":"32303","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Tulsa","Latitude":"36.1237711","CountryDisplay":"United States","Longitude":"-95.9488975","Name":"GSK Investigational Site","StateDisplay":"Oklahoma","PostalCode":"74114","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"}],"masking":"Open Label","maximum_age_raw":"N/A N/A","maximum_age":"N/A","minimum_age":"18","minimum_age_raw":"18 Years","modified_date":"10/01/2018 23:05:05","number_of_arms":"1","observational_design":{"biospecimen_description":"","biospecimen_retention":"","number_of_groups":"","observational_study_design":"","patient_registry":"","target_duration_quantity":"","target_duration_units":"","timing":""},"official_title":"A phase IV, open-label, multicenter study of treatment with TRIZIVIR (abacavir 300mg/lamivudine 150mg/zidovudine 300mg) twice daily and tenofovir 300mg once-daily for 48 weeks in HIV-infected subjects experiencing early virologic failure (ZIAGEN Intensification Protocol)","org_study_id":"ESS 30005","overall_contact":{"email":null,"last_name":"US GSK Clinical Trials Call Center","phone":"877-379-3718"},"overall_status":"Completed - Interventional","oversight_info":{"exported_from_us":"","fda_regulated_device":"","fda_regulated_drug":"","ped_postmarket_surv":"","has_dmc":null,"post_prior_to_approval":"","regulatory_authorities":[""]},"phase":"Phase 4","primary_compl_date":"08/01/2004 00:00:00","primary_outcomes":[{"outcome_description":"","outcome_measure":"HIV viral load response at 48 weeks as measured by proportion of subjects with undetectable viral load.","outcome_time_frame":"48 weeks","outcome_safety_issue":null}],"product_name":"","product_name_OneLinkTx":"","secondary_ids":[],"secondary_outcomes":[{"outcome_description":"","outcome_measure":"Safety Viral load response at 24 weeks Change in T-cell count Resistance Health outcomes","outcome_time_frame":"24 weeks","outcome_safety_issue":null}],"sponsors":{"investigator_affiliation":"","investigator_username":"","lead_sponsor":"ViiV Healthcare","collaborators":[]},"start_date":"03/01/2002 00:00:00","study_type":"interventional","therapeutic_area":"Infectious Diseases","citations":[],"is_section_801":null}},"pageContext":{"studyId":"ESS 30005"}},"staticQueryHashes":["162689979","3332233851","3729204765","3769354840","399703114"]}